Kamada
American Red Cross
Kamada (Israel) and the American Red Cross (Washington, DC) received funding from the BIRD Foundation to develop an Alpha1-Proteinase Inhibitor from Human source for Alpha-1-Antitrypsin Deficiency patients.
The Alpha-1 Anti-Trypsin (AAT) Protein was extracted and administered by infusion to patients whose livers are unable to naturally synthesize it. This project was completed with the preparation of a clinical grade Active Pharmaceutical Ingredient and resulted in an IND submission to the FDA. This submission led to successful clinical trials resulting in FDA approval in July 2010. Kamada reached a major licensing agreement with Baxter International to distribute intravenous Alpha 1 Antitrypsin Product for the treatment of hereditary Alpha-1 antitrypsin Deficiency under the trade name “Glassia™”.
Approved 1999
